Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

ALKEM LABORATORIES LTD.

NSE : ALKEMBSE : 539523ISIN CODE : INE540L01014Industry : Pharmaceuticals & DrugsHouse : Private

BSE5343.50-91.5 (-1.68 %)

PREV CLOSE ( ) 5435.00

OPEN PRICE ( ) 5433.90

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 1205

TODAY'S LOW / HIGH ( )5275.00 5434.90

52 WK LOW / HIGH ( )4627.9 5933

NSE5344.50-91 (-1.67 %)

PREV CLOSE( ) 5435.50

OPEN PRICE ( ) 5401.00

BID PRICE (QTY) 5344.50 (131)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 145051

TODAY'S LOW / HIGH( ) 5259.00 5419.50

52 WK LOW / HIGH ( )4611.85 5933.5

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 08-08 1973

Management Info

Basudeo N Singh - Chairman Sandeep Singh - Managing Director

Registered Office

Address Alkem House,Senapati Bapat Marg,Lower Parel (West),
Mumbai,
Maharashtra-400013

Phone 022 3982 9999

Email investors@alkem.com / contact@alkem.com

Website www.alkemlabs.com

Registrars Details

MUFG Intime India Pvt Ltd.

C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai

Listing : BSE, NSE

NEWS

23Mar Alkem Laboratories launches semaglutid
Alkem Laboratories has launched semaglutide injection in India under the..

21Mar Alkem Laboratories informs about updat
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosur..

21Mar Alkem Laboratories informs about press
Alkem Laboratories has informed that it enclosed Press release on Alkem..

16Mar Alkem Laboratories gets certificate of
Alkem Laboratories has received a ‘Certificate of GMP Compliance of a Ma..

16Feb Alkem Laboratories reports marginal ri
Alkem Laboratories has reported results for third quarter ended December..

Financials

Rs. in Millions

	QTR Dec 25	ANNUAL 25
Net Profit	6221.4	22808.9
Gross Profit	7061.5	23035.4
Operating Profit	8207.4	26632.6
Net Sales	24912.7	88134.4

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Onesource Specialty (BSE) 1452.15 (6.99%)	M.Cap ( in Cr)16644.72
Emcure Pharma (BSE) 1653.60 (3.75%)	M.Cap ( in Cr)31350.53
Anthem Biosciences (BSE) 681.20 (5.44%)	M.Cap ( in Cr)38263.95
Mankind Pharma (BSE) 2040.25 (0.99%)	M.Cap ( in Cr)84227.30
Gland Pharma (BSE) 1728.75 (1.16%)	M.Cap ( in Cr)28482.27

Shareholding Pattern

	PROMOTERS	51.2%
	NON-INSTITUTION	17.3%
	MUTUAL FUNDS/UTI	16.06%
	FI/BANKS/INSURANCE	3.96%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
Tata Nifty MidSmall...	4.49
Motilal Oswal Nifty...	4.47
ICICI Pru Pharma He...	4.01
NJ ELSS Tax Saver S...	3.58
LIC MF Healthcare F...	3.50
ICICI Pru Nifty Pha...	3.36
Nippon India Nifty ...	3.36

Risk Disclosures on Derivatives

Smart Quotes

ALKEM LABORATORIES LTD.